Previous 10 | Next 10 |
Shares of Organon (NYSE: OGN) fell 15% on Thursday. The pharmaceutical company, which focuses on women's health therapies, established medicines, and biosimilars, reported fourth-quarter and full-year numbers that came in below analysts' consensus expectations. The stock ended the session...
Organon & Co (OGN) Q4 2022 Earnings Conference Call February 16, 2023, 08:30 ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO & Director Matthew Walsh - EVP & CFO Conference Call Participants Terence Flynn - Morgan Stanley U...
Organon ( NYSE: OGN ) stock fell ~4% premarket on Thursday after Q4 results missed estimates. Q4 adjusted EPS declined -28.3% Y/Y to $0.81. Revenue fell -7.4% Y/Y to ~$1.49B but grew +1% Y/Y excluding the impact of foreign currency (ex-FX). "Since these products have been ...
Organon press release ( NYSE: OGN ): Q4 Non-GAAP EPS of $0.81 misses by $0.10 . Revenue of $1.49B (-6.9% Y/Y) misses by $10M . Shares -1.2% PM. Full year 2023 financial guidance provided; full year revenue range of $6.150 billion to $6.450 billion vs. $6.3...
Full year 2022 revenues of $6.2 billion; all three franchises contribute to growth on constant currency basis Full year 2022 diluted earnings per share from continuing operations of $3.59 and non-GAAP Adjusted diluted earnings per share from continuing operations of $5.03 Full year 2022 A...
Summary It’s among the prohibitively expensive biologic pharmaceuticals being replaced by cheaper “biosimilar” copycats. Relief is on the way for patients who need Humira, a product made by AbbVie. Several drugmakers are expected to begin offering biosimilar ver...
Organon ( NYSE: OGN ) is scheduled to announce Q4 earnings results on Thursday, February 16th, before market open. The consensus EPS Estimate is $0.91 (-33.6% Y/Y) and the consensus Revenue Estimate is $1.5B (-6.3% Y/Y). Over the last 1 year, OGN has beaten EPS estimates 1...
Summary Viatris and Organon are what can currently be described as "deep value plays" in the pharmaceutical sector. They face largely similar challenges, but on closer inspection are quite different companies. While I have already reported on Viatris' ever-changing portfolio, in this ar...
Summary Organon has a solid portfolio driven by steady established brands and fast-growing Women's Health. Management is exercising balance sheet discipline by paying down debt all while maintaining a very well covered dividend. Investors could potentially see strong total returns f...
Summary Organon is a business I own - but only due to being awarded a significant number of shares, some of which I actually sold early on. I kept a stake. In this article, I'm going to follow a subscriber request and dive into what Organon might do for its shareholders, if you did not ...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...